ライフサイエンスコーパス: inhibitor

1 parenteral anticoagulants plus glycoprotein inhibitors).

2 t by expression of the p16(INK4a) cell-cycle inhibitor.

3 vity analyses included evolocumab as a PCSK9 inhibitor.

4 A replication despite the presence of a Cdk2 inhibitor.

5 s, this N-TIMP2 mutant acted as a functional inhibitor.

6 was dominant and showed no synergy with the inhibitor.

7 lecular mechanism of EGCG as a neurotoxicity inhibitor.

8 th AsiDNA, a novel first-in-class DNA repair inhibitor.

9 combined treatment with osimertinib and SFK inhibitors.

10 er a new strategy for the development of HIV inhibitors.

11 poultry animals; and the use of gastric acid inhibitors.

12 ied as potent ATP-competitive protein kinase inhibitors.

13 tify further investigation of AT with kinase inhibitors.

14 ed to the increased tumor resistance to BRAF inhibitors.

15 backbone of Nucleoside Reverse Transcriptase Inhibitors.

16 umor immunity, and provide an update on mTOR inhibitors.

17 sistent state in response to targeted kinase inhibitors.

18 nes of various histological origins with JAK inhibitors.

19 lly altered the potency for individual URAT1 inhibitors.

20 ally bulky HDAC6-selective phenylhydroxamate inhibitors.

21 creased haematocrit levels noted with SGLT-2 inhibitors?

22 mice that overexpress plasminogen activator inhibitor-1 (PAI-1), S. aureusclfA expression and fibrin

23 n twice-weekly recombinant human C1 esterase inhibitor, 13 (45%) of 29 patients given the once-weekly

24 topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clini

25 We report that the RR inhibitor 3-AP actively induces PEL cell cycle arrest th

26 ur transient incubation in the four chemical inhibitors (4i)-naive reprogramming medium and showed tr

27 ed cation currents were blocked by the TRPM4 inhibitor 9-phenanthrol in both groups.

28 Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pa

29 traints also explain one-third of allosteric inhibitors, a finding rationalized by crystallographic a

30 mini contribute to transporter substrate and inhibitor affinities.

31 nd imidazoles were synthesized and tested as inhibitors against muscle and liver isoforms of glycogen

32 ATP-competitive inhibitors against this complex have been recently advan

33 RAF inhibitors also enhance RAS-RAF association.

34 onse were ameliorated by the cytochrome P450 inhibitor aminobenzotriazole.

35 re of LmFBPase complexed with its allosteric inhibitor AMP shows an inactive form of the tetramer, in

36 ntitative real-time-PCR analysis followed by inhibitor and antibody-blocking assays revealed that the

37 nin containing TCP1 subunit 6A (CCT6A) as an inhibitor and direct binding protein of SMAD2 and found

38 Using full-dose proton-pump inhibitor and high-dose Metronidazole in group A, and fu

39 udil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in p

40 dazole in group A, and full-dose proton-pump inhibitor and prescription from a Gastroenterologist in

41 te offers a novel target site for allosteric inhibitors and a molecular explanation for the previousl

42 glioblastoma cells enabled expression of CDK inhibitors and decreased p53 protein turnover, which blo

43 for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to

44 through a cascade that was sensitive to ERK inhibitors and pertussis toxin.

45 FBS) and a glycogen synthase kinase-3 (GSK3) inhibitor, and in serum-free media.

46 ipid substrates for enzymatic assays, potent inhibitors, and chemical probes to detect, track, and ch

47 nylate cyclase activators, phosphodiesterase inhibitors, and most notably by stimulation of G protein

48 liflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes.

49 While a number of pan-FGFR inhibitors are being clinically evaluated, their applica

50 hysical characterization shows that the best inhibitors are competitive with acetyl coenzyme A and an

51 sugar sodium-glucose cotransporter 2 (SGLT2) inhibitors are highly promising drug candidates for the

52 c to treat leukemia, but tight and selective inhibitors are not available for Bcl-2 paralog Bfl-1.

53 tments, such as selective serotonin reuptake inhibitors, are not ideal because only a fraction of pat

54 by N-TIMP2 and identifies a promising MMP-14 inhibitor as a starting point for the development of pro

55 pment of small molecule Gas6-TAM interaction inhibitors as a novel class of cancer therapeutics.

56 Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-ampli

57 minishes the anti-tau potency of Hsp90/Hsc70 inhibitors as well as Hsc70 variants (WT & E175S).

58 en together, the findings suggest that Hsp70 inhibitors as well as their hybrids can serve as potenti

59 perties similar to those of another chemical inhibitor, AS-48, which appears to interfere with the co

60 ity in patients treated with tyrosine kinase inhibitors at levels not detectable via dermatological i

61 Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite format

62 to be gained by early conversion to an mTOR inhibitor-based maintenance regime.

63 g therapy and a responder given a checkpoint inhibitor-based regimen because of a mismatch repair gen

64 nases via capture on immobilized multiplexed inhibitor beads with subsequent proteolytic digestion of

65 beled verinurad revealed that distinct URAT1 inhibitors benzbromarone, sulfinpyrazone and probenecid

66 Bromodomain and extraterminal domain inhibitors (BETi) represent promising therapeutic agents

67 substitutions (T124N/T174I) directly weaken inhibitor binding at the dimer interface of the catalyti

68 Bumped kinase inhibitors (BKIs) of Cryptosporidium parvum calcium-depe

69 The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone

70 es have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been u

71 py (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option a

72 Corrosion inhibitors can affect calcium carbonate precipitation an

73 nistration of peripherally restricted NaV1.7 inhibitors can only produce analgesia when administered

74 lts suggest that 3TSR, or other angiogenesis inhibitors, can be repurposed for TSP1 replacement thera

75 Checkpoint kinase inhibitors (CHKi) exhibit striking single-agent activity

76 red a highly selective and potent BTK kinase inhibitor (CHMFL-BTK-11) which exerted its inhibitory ef

77 r of cyclin-dependent kinases (CDKs) and CDK inhibitors (CKIs), the expression of which is often dysr

78 ther imide-based natural product translation inhibitors, CL engages in a particularly interesting and

79 omavirus-associated nephropathy, calcineurin inhibitors (CNI), and genetic factors.

80 ystallography study of the rabbit muscle GPb inhibitor complexes revealed structural features of the

81 The pharmacologic PKC-theta inhibitor (Compound 20) administered during allergen cha

82 determine the effects of differentiation and inhibitor concentration on protease expression.

83 inding to C3b clusters in the presence of C5 inhibitors correlated with the levels of residual hemoly

84 lly perturbing Fus3 dynamics with a specific inhibitor could effectively redirect the mating differen

85 e, we report that specific protein synthesis inhibitors could either significantly increase T-box-med

86 Selective inhibitors could help unveil the mechanisms by which inh

87 NQO1/TRXR1 axis with its specific and potent inhibitors could lead to promising host-directed therape

88 GSK2879552, a lysine demethylase 1 inhibitor currently in clinical trials for the treatment

89 Compound III, a selective MMP7 inhibitor, decreased development of invasive prostate ca

90 Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpr

91 as the classic drug target to develop fusion inhibitors derived from the gp41 CHR.

92 Furthermore, using the Notch inhibitor dibenzazepine (DBZ) to drive cellular differen

93 In this series, MEK inhibitors did not cause irreversible loss of vision or

94 nduction of HLA class-I by interferons, HDAC inhibitors did not interfere with the expression of immu

95 iable epidermis skin layer; whereas for BRAF inhibitors, discriminative power was 71%.

96 For MEK and EGFR inhibitors, discriminative power was more than 90% in th

97 scovery of a highly selective PI3Kbeta/delta inhibitor displaying excellent pharmacokinetic profile a

98 Treatment with CSF1R inhibitors disrupted this crosstalk and triggered a prof

99 We also noted that this inhibitor does not dissociate the Aha1-Hsp90 complex but

100 ma drug concentration of the viral integrase inhibitor dolutegravir.

101 ne analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub-Saharan Afric

102 either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boosted Protease Inhibitor

103 Pore inhibitors elevate the electrical threshold for spreadin

104 f Ascl1, together with a histone deacetylase inhibitor, enables adult mice to generate neurons from M

105 Consistently, PI3Kdelta inhibitors enhanced AID expression and translocation fre

106 ractile activity, which was shown by pathway inhibitor experiments and Western blot analysis to be me

107 lpha1-antitrypsin protein (a serine protease inhibitor) expression and downregulation of neutrophil e

108 ly-expressed member of the cysteine protease inhibitor family that is present at notably high concent

109 We find that the inhibitor fasudil enhances action-outcome memory, result

110 ond case, the affinities of a broad-spectrum inhibitor for 22 bromodomains were calculated and return

111 to determine the effectiveness of a chemical inhibitor for FAP in mice.

112 Specific inhibitors for ERK1/2 MAPK (PD98059), p38 MAPK (SB203580

113 esting a novel therapeutic approach with p38 inhibitors for future clinical application.

114 als, and is an exciting prospect to identify inhibitors for the many other viral pathogens of signifi

115 foci in 50 eyes of 25 patients receiving MEK inhibitors for treatment of their metastatic cancer, who

116 al to establish outcome-specific conditioned inhibitors for two distinct appetitive outcomes.

117 also given injections of single or combined inhibitors; growth of these patient-derived xenograft tu

118 model) were exposed to a brain-penetrant GCS inhibitor, GZ667161.

119 of CETP (cholesteryl ester transfer protein) inhibitors has had a long and difficult course with 3 co

120 Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian

121 Buparlisib, a pan-PI3K inhibitor, has shown preclinical antitumour activity and

122 Although several Cyp inhibitors have been reported in the literature, it has

123 tly, clinical trials with Janus kinase (JAK) inhibitors have shown that cytokine receptors that signa

124 lied to a rapid synthesis of the spliceosome inhibitor herboxidiene.

125 s approach, an optimized macrocyclic peptide inhibitor (HL2-m5) was obtained that binds Shh with a KD

126 in mice treated with a hedgehog (Hh) pathway inhibitor (HPI), and that gustatory nerves are a source

127 plasmodial activity of the aspartic protease inhibitor hydroxyl-ethyl-amine-based scaffold compound 4

128 K1/2 inhibitors (such as ruxolitinib and JAK inhibitor I) strongly stimulate VSV replication and onco

129 food-induced anaphylaxis with the ABL kinase inhibitor imatinib protected the mice from severe IgE-me

130 scaffold and structural insights for further inhibitor improvement.

131 ed protein kinase (AMPK) as a beta1-integrin inhibitor in fibroblasts.

132 days of incubation with the TGFbeta receptor inhibitor in the presence of trastuzumab, caused cells t

133 a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multi

134 The list prices of PCSK9 inhibitors in the United States (>$14,500 per year) are

135 ase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocul

136 nthracyclines including doxorubicin and CDK9 inhibitors including dinaciclib that synergized with ABT

137 ermal growth factor receptor tyrosine kinase inhibitors, including gefitinib, erlotinib, and afatinib

138 with neutralizing anti-IL-2 Ab or STAT5/JAK3 inhibitors, indicating that STAT5 signaling drives RICD

139 h the pocket occupied by some H3 HA-specific inhibitors, indicating the high relevance of this cavity

140 arkably, codelivery of activin and myostatin inhibitors induced a synergistic response, resulting in

141 Lastly, combination of AURKA and MEK inhibitors induces a deleterious effect on mutant KRAS c

142 idelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy

143 Insofar as kinase inhibitors interfere with signaling dynamics, and, in tu

144 e described the evolution of a reported PI3K inhibitor into a moderate PI3Kalpha inhibitor with a low

145 Because the production of each inhibitor is promoted by a regulatory protein that is it

146 data suggest that resistance to BRAF or MEK inhibitors is probably inevitable, and novel therapeutic

147 ismodegib, a first-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced b

148 peptidase becomes covalently attached to the inhibitor, is dragged 75 A apart, and is irreversibly in

149 nding studies disclosed that the competitive inhibitor isoeugenol is predominantly in its deprotonate

150 Treatment with an Aha1 inhibitor, KU-177, dramatically reduced the accumulation

151 Treatment with specific GSK3 inhibitor (L803-mts), starting from 4 hours after 600 mg

152 esis of a focused histone deacetylase (HDAC) inhibitor library with peptoid-based cap groups and diff

153 o determine the efficacy of a PI3K/mTOR dual inhibitor, LY3023414, on established EAC in an in vivo m

154 Chk1 inhibitors may be a potentially useful therapeutic treat

155 medication such as phosphodiesterase type 5 inhibitors may be beneficial, and surgery remains an opt

156 g is commonly activated in cancer, tankyrase inhibitors may have therapeutic potential in targeting t

157 argeting both receptors with STAT3 signaling inhibitor might be a therapeutic approach for the treatm

158 T-loop conformation whereas addition of the inhibitors MLN8054 and CD532 favors an inactive T-loop.

159 ritoneal injection of the HuR small-molecule inhibitor MS-444 in AOM/DSS mice, a model of IBD and inf

160 hich progression occurred included aromatase inhibitor (n = 36), fulvestrant (n = 21), and tamoxifen

161 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are associated wi

162 adblock in the discovery of nonnucleoside RT inhibitors (NNRTIs).

163 A selective peptide inhibitor of AMPH-dependent trafficking of the neuronal

164 ed virgin olive oil consumption, is a strong inhibitor of angiogenesis ex vivo and in vivo.

165 Survivin, an inhibitor of apoptosis (IAPs) family member, exhibited a

166 rotein known as viral mitochondria-localized inhibitor of apoptosis (vMIA) traffics from the ER to mi

167 Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-d

168 ugs, and, in particular, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).

169 ditionally, the compound is a noncompetitive inhibitor of daunorubicin (MRP1), calcein AM (P-gp), and

170 Inhibitor of DNA binding (Id) proteins play important ro

171 rin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced

172 of PELP1-cyto HMECs showed up-regulation of inhibitor of kappaB kinase (IKK) and increased phosphory

173 sting that it may provide a highly selective inhibitor of MEK1/2 for use as a cancer therapeutic.

174 Transfection of MCs with mimic or inhibitor of miR-4443 resulted in decreased or enhanced

175 CFI-402257 is a novel, selective inhibitor of Mps-1 with antineoplastic activity.

176 n the presence of rapamycin, a pharmacologic inhibitor of mTORC1, we were able to identify six T-bet

177 ulation were reversed by IDH-C35, a specific inhibitor of mutant IDH1.

178 en, the newly synthesized Daunorubicin is an inhibitor of neuronal excitability.

179 Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhi

180 IRAK-M, also known as IRAK-3, is an inhibitor of proinflammatory cytokine and chemokine expr

181 yer containing docetaxel and clinically used inhibitor of sphingosine kinase 1 (SK1) FTY720 (fingolim

182 These results show that VPA is a potent inhibitor of STAT3 phosphorylation and demonstrate that

183 uptake in the presence of glibenclamide, an inhibitor of the ATP-dependent potassium (KATP)-channels

184 fects of a recently developed small-molecule inhibitor of the KDM5 family of proteins (KDM5i), either

185 It is a potent inhibitor of the mRNA decapping scavenger enzyme (DcpS),

186 Glycosylated mandelalides are effective inhibitors of aerobic respiration in living cells.

187 /UNC84A and SUN2/UNC84B are potent or modest inhibitors of HIV-1 infection, respectively, and that su

188 ime a series of novel, potent, and selective inhibitors of IKKalpha.

189 ork identifies TGF-beta1 and BMP-2 as potent inhibitors of IL-34 expression in RA synovial fibroblast

190 Clinically approved inhibitors of MBLs are currently unavailable as design h

191 we investigate the antidepressant actions of inhibitors of monoacylglycerol lipase (MAGL), the major

192 t enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependen

193 zebrafish development that can be blocked by inhibitors of PAK or MEK.

194 of RT-QuIC to identify potential therapeutic inhibitors of prion conversion.

195 Experiments with inhibitors of protein kinase G (PKG), protein kinase A (

196 e current status of exogenous small-molecule inhibitors of RAGE and concludes by identifying key stra

197 electrostatics with few, hitherto best known inhibitors of SOCE.

198 Using selective peptide inhibitors of the CXCL1-CXCR2 signaling axis identified

199 of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6

200 AML cells, enabling apoptotic sensitivity to inhibitors of the DNA replication checkpoint and suggest

201 sing an unbiased phenotypic screen to detect inhibitors of the HSF1 stress pathway.

202 iazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxy

203 We discuss how small-molecule inhibitors of the tryptophan (Trp) catabolic enzyme indo

204 the distal step in LTB4 synthesis and hence inhibitors of this enzyme have been actively pursued.

205 ore have the potential to act as competitive inhibitors of this interaction.

206 NADP (NADPH) oxidase pathway modulators and inhibitors of Toll-like receptors (TLRs).

207 a reliable readout for effects of CDK4/CDK6 inhibitors on cell proliferation.

208 The efficacy of NHE inhibitors on the risk of cardiovascular events may be e

209 Administration of Manoalide, a PLA2 inhibitor or Zileuton, a 5-LOX inhibitor with VPC revers

210 rolidine dithiocarbamate (PDTC, an NF-kappaB inhibitor) or SB203580 (a MAPK inhibitor) showed signifi

211 ter treatment with olaparib (n = 14), a PARP inhibitor, or iniparib (n = 11), which has no PARP inhib

212 s prevented by an antioxidant, mitochondrial inhibitors, or inhibition of NO formation.

213 integrin blocking antibodies, pharmacologic inhibitors, phosphoproteomics, and Western blot analysis

214 hibitors (EFV) or ritonavir-boosted Protease Inhibitors (PI) with the same backbone of Nucleoside Rev

215 d with the p38gamma-specific pharmacological inhibitor pirfenidone.

216 ltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety.

217 INTERPRETATION: Protease inhibitor plus raltegravir offered no advantage over pro

218 hened antitumor responses to the BRAF(V600E) inhibitor PLX4720 in both BVE(Cyp24a1-null) and BVE(Cyp2

219 ERK1/2) was blocked by the Src family kinase inhibitor PP2, indicating that the action of pilocarpine

220 However, PI3K inhibitors primarily induce cell cycle arrest, leaving a

221 n wild-type (WT) mice pretreated with a PKal inhibitor prior to tPA.

222 of the pY88-H4 epigenetic marks by the ACK1 inhibitor (R)-9bMS-sensitized naive and enzalutamide-res

223 Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrh

224 osphonocarboxylates, the first reported RGGT inhibitors, rationally improve understanding of their st

225 locking studies with preinjection of a CXCR4 inhibitor reduced (125)I-pentixafor uptake in atheroscle

226 Additionally, combined ERK and p65 NFkappaB inhibitors reduced p27 expression and potentiated apopto

227 agliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortalit

228 nutrient starvation or use of an active site inhibitor reduces Skp2 levels and stabilizes LT, leading

229 nstant (Ki ) of 0.9 pm, the strongest MMP-14 inhibitor reported so far.

230 nd AXL and the promiscuity of small molecule inhibitors represent important challenges faced by curre

231 Thus, ROCK inhibitors represent potential therapeutics for VHL-defi

232 our findings suggest that the dual-activity inhibitor represents a highly promising lead compound fo

233 Ceftazidime/inhibitor resistant mutants hyperproduce L1, but retain

234 Members of the TRANSPORT INHIBITOR RESPONSE1/AUXIN SIGNALING F-BOX PROTEIN (TIR1/

235 cs, and, in turn, signaling dynamics affects inhibitor responses, we investigated associations in thi

236 Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sens

237 r treatment with Fluoxetine, a 5-HT reuptake inhibitor, restored normal breathing.

238 Furthermore, a selective Mcl-1 inhibitor restores regorafenib sensitivity in CRC cells

239 t of WAP-Int3 tumor bearing mice with an IKK inhibitor resulted in tumor regression.

240 DLD-1 cells were transfected with small inhibitor RNAs against PPP1R1, injected into the tail ve

241 parenteral anticoagulants plus glycoprotein inhibitors; RR 1.88 [1.24-2.86] for reteplase plus paren

242 FA or sham treatment with or without a STAT3 inhibitor (S3I-201 or micellar curcumin, eight arms).

243 synthesized dihydropyridopyrimidine pan-BET inhibitor scaffold, which was uncovered via a virtual sc

244 ing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for

245 L-2Rgamma induced cell death in selected JAK inhibitor-sensitive cells.

246 ed benefit from selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor us

247 an NF-kappaB inhibitor) or SB203580 (a MAPK inhibitor) showed significantly improved potential for o

248 Treatment with a Syk inhibitor significantly reduced renal allograft injury i

249 Abnormalities were blocked by the mTORC1 inhibitor sirolimus.

250 ly, the store-operated calcium entry channel inhibitor (SK&F96365) also reduced MSU crystal-induced N

251 In particular, the histone deacetylase inhibitor sodium butyrate (SB) may indirectly (through r

252 herapy (CBT) or selective serotonin reuptake inhibitors (SSRIs).

253 JAK1/2 inhibitors (such as ruxolitinib and JAK inhibitor I) str

254 The treatment of cells with pharmacological inhibitors, such as nonsteroidal anti-inflammatory drugs

255 utants hyperproduce L1, but retain aztreonam/inhibitor susceptibility because aztreonam is not an L1

256 g is controlled by the BMP/Chordin activator/inhibitor system.

257 lead for further development of cathepsin G inhibitors targeting chronic inflammatory disorders.

258 d ubiquitin variant (UbV) library to develop inhibitors targeting the DUBs USP7 and USP10, which are

259 report several series of pyrazolopyran-based inhibitors targeting the enzyme serine hydroxymethyltran

260 Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is particularly act

261 the modern nucleoside reverse transcriptase inhibitor tenofovir.

262 tingly, BCNS-BCCs are more responsive to SMO inhibitors than sporadic BCCs, with minimal development

263 selective vesicular monoamine transporter 2 inhibitor that demonstrated favorable efficacy and toler

264 Upon addition of a covalent inhibitor that mimics one of the reaction intermediates,

265 domain from cholesterol, or by providing an inhibitor that overrides this cholesterol activation.

266 Overall, our findings show how GSK-3 inhibitors that downregulate PD-1 expression can enhance

267 .Significance: These findings show how GSK-3 inhibitors that downregulate PD-1 expression can enhance

268 cannot be distinguished by conventional Src inhibitors that target the kinase domain.

269 ggesting it as a candidate biomarker for ATR inhibitor therapy.

270 rombospondin-1 (TSP1), a potent angiogenesis inhibitor, through epigenetic regulation.

271 The CDK7 inhibitor, THZ1 prevented Ser118 phosphorylation and inh

272 s and following conventional tyrosine kinase inhibitor (TKI) treatment.

273 Here the authors show that a chemical inhibitor to a viral fusion protein is effective in redu

274 Administration of an inhibitor to cyclooxygenase-2, the initiating enzyme in

275 oprevir's higher potency than simeprevir, an inhibitor to which the double substitution confers a sig

276 The addition of glycoprotein IIb or IIIa inhibitors to fibrinolytic therapy increased the risk of

277 es directed at the design of efficient entry inhibitors to minimize the development of resistance by

278 (E)-alpha-bergamotene and trypsin proteinase inhibitors (TPIs), which are also found in herbivore-ind

279 inhibitor/serotonin-norepinephrine reuptake inhibitor use and 11 studies reported morbidity in patie

280 sk factors for iron deficiency, gastric acid inhibitor use for >/=2 years was associated with an incr

281 rypsin (AAT; Prolastin-C), a serine protease inhibitor used for the treatment of AAT deficiency, inhi

282 t 38u might act as a potent and specific AEP inhibitor useful for cancer treatment.

283 ity relationship assessment of adenine-based inhibitors using biochemical and docking methods.

284 human CD4(+) T cells, a 5-d exposure to BET inhibitors was accompanied by a significant downregulati

285 In search of RSV inhibitors, we have integrated a signature resistance mu

286 ience disease progression with targeted BRAF inhibitors, we hypothesized therapeutic response is rela

287 P2X7(-/-) mice and mice treated with a P2X7 inhibitor were protected from diabetes-induced TNF-alpha

288 These inhibitors were shown to possess a novel binding mode by

289 are simultaneously reduced by Hsp90 or Hsc70 inhibitors, whereas overexpression or knockdown of RanBP

290 lar to more potent vacuolar-type H(+)-ATPase inhibitors, which all inhibited LGR5 internalization by

291 site of these aniline-based influenza fusion inhibitors, which significantly overlaps with the pocket

292 Combining CSF1R inhibitor with a CXCR2 antagonist blocked granulocyte in

293 ted PI3K inhibitor into a moderate PI3Kalpha inhibitor with a low molecular weight.

294 we reported a novel thienopyrimidinone SIRT2 inhibitor with good potency and excellent selectivity fo

295 alide, a PLA2 inhibitor or Zileuton, a 5-LOX inhibitor with VPC reversed the protective effects of VP

296 Our results provide novel Sirt2 inhibitors with a compact scaffold and structural insigh

297 Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways ma

298 reversible and selective human factor D (FD) inhibitors with drug-like properties.

299 of nonnucleoside, reversible, small-molecule inhibitors with greater specificity against hRRM1 is a k

300 These substitutions led to inhibitors with increased PACE4 selectivity and potent a